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Abstract: Fibroblast growth factor 23 (FGF23) has recently been identified as a critical regulatory factor in phosphate (P) metabolism. 
Although the exact molecular mechanism of FGF23 synthesis through sensing the concentration of P is yet to be determined, experimental 
and clinical data indicate the influential role of FGF23 in P and calcium (Ca) homeostasis. Here, we extended our previous mathematical 
model in calcium regulation and examined the conceivable roles of FGF23 in mineral metabolism. We assumed that the level of 
FGF23 was controlled through the concentrations of P and calcitriol in serum, and its actions such as lowering of the renal threshold 
for P, inhibition of the production of calcitriol in the kidney tubule, and inhibition of the production of parathyroid hormone (PTH) 
were included. Comparisons between the models with and without FGF23 demonstrate a complex interplay of FGF23 with calcitriol 
and PTH. In consistent with the model, our in vitro experimentation indicates that expression of FGF23 is activated in the presence 
of P though a G-protein linked receptor. We expect that further efforts on modeling and experimental evaluation would contribute to 
diagnosing patients with metabolic diseases such as osteoporosis and chronic kidney diseases, and developing FGF23-linked treatment 
strategies.
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Introduction
The FGF family consists of 22 members for various 
functions  in  embryonic  development,  cellular 
proliferation  and  differentiation,  tissue  repair,  and 
tumor  growth  and  invasion.  FGF23  has  recently 
been demonstrated to represent a critical circulating 
hormone  involved  in  phosphate  metabolism.  It 
is  an  approximately  32-kD  (251  amino  acids) 
protein and its N-terminal region contains the FGF 
homology domain.1 The primary function of FGF23 
is  considered  to  be  inhibition  of  reabsorption  of 
renal tubular phosphate.2 However, many questions 
are  unanswered  for  the  role  of  FGF23  in  mineral 
metabolism with regards to known regulators such 
as PTH and calcitriol.3,4 Thus, a traditional regulatory 
mechanism with PTH and calcitriol needs to be rebuilt 
in accordance with the actions of FGF23.
Understanding  the  mechanism  of  Ca  and  P 
metabolism  requires  multiscale  mathematical 
modeling.  Behaviors  of  this  highly  interactive, 
nonlinear process can hardly be predicted by simple 
intuition.  FGF23  is  primarily  synthesized  in  bone 
but its site of action is the kidney. Although genetic 
and  biochemical  analyses  are  essential  to  identify 
regulatory  mechanisms,  those  approaches  alone 
will not be sufficient to quantitatively evaluate the 
key  processes  and  develop  effective  therapeutic 
interventions  for  patients  undergoing  hemodialysis 
and  patients  with  metabolic  disorders.  Various 
mathematical  models  have  been  developed  for 
calcium homeostasis.5–8 However, few models have 
been  formulated  including  phosphate  metabolism. 
Several models are proposed for bone remodeling,9–11 
but mineral metabolism in the kidney is not included. 
To  our  knowledge,  no  comprehensive  models  for 
calcium  and  phosphate  metabolism  are  available 
including the role of PTH and FGF23.
In this study, we included the actions of FGF23 
to  a  previously  published  mathematical  model  of 
calcium and phosphate metabolism8 and investigated 
the potential influence of FGF23 on the observable 
state variables such as the serum concentrations of 
PTH, calcitriol, Ca, P, and the urinary excretion of Ca 
and P. In order to support the mechanism of sensing 
P in bone through a G-linked protein receptor, we 
conducted two in vitro experiments to evaluate the 
mRNA expression level of FGF23 using MLO-A5 
osteocyte-like cells.12 The first experiment was aimed 
to examine whether expression of FGF23 would be 
elevated in the presence of P in a culture medium, 
while  the  second  experiment  using  an  inhibitor  to 
G-linked protein receptors was designed to evaluate 
their potential role in sensing the level of P in bone. 
The  specific  questions  addressed  in  the  present 
modeling  study  included:  How  does  an  increase 
in the concentration of FGF23 affect the actions of 
calcitriol and PTH? And how does alteration in the 
concentration  of  calcitriol  or  PTH  modulate  the 
FGF23 concentration and the absorption and excretion 
levels of P? The model was built with and without 
the  predicted  effects  of  FGF23,  and  the  dynamic 
responses were numerically evaluated in a transient 
time frame (0–100 h) as well as at 2000 h.
Model, Materials and Methods
Modeling dynamical exchange 
processes
The present work with the action of FGF23 is an 
extension of a previously published model without 
FGF23.8  In  brief,  the  mineral  metabolism  in  the 
previous model was treated as exchange processes at 
three interfaces: intracellular and extracellular spaces 
for P; extracellular space and bone for Ca and P; and 
extracellular space and the outside world (through 
ingestion  and  excretion)  for  Ca  and  P  (Fig. 1A). 
These exchanges were controlled by two endocrine 
factors—PTH and calcitriol, which were assumed to 
be confined to the extracellular compartment.
Considered in the previous model were the functional 
compartments, which represented the secretory mass 
of the parathyroid glands, the pools of transporting 
intestinal  translocators  for  Ca  and  P,  the  pools  of 
renal tubular translocators for Ca and P, and the pool 
of  the  tubular  1-hydroxilating  enzyme  (converting 
calcidiol into calcitriol). With the exception of the 
parathyroid gland secretory mass that was assumed 
to remain constant, the dynamics of the pools were 
modeled  with  the  first-order  nonlinear,  diffusional, 
differential equations. A modeling principle was that 
the instantaneous rate of variation of the pool size was 
equal to the sum of the influxes minus the sum of the 
effluxes. Thus, the dynamical exchange processes in 
each of the compartments was represented by a time 
derivative of 8 pools in a general form:
  d(Qx)/dt = ∑Jinflux(x) - ∑Joutflux(x)  (1)FGF23 in mineral metabolism
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where Q = size of  the pool of the state variable x (e.g. Ca 
in bone); J(x)influx = influxes of variable x (e.g. intestinal 
uptake of P); and J(x)outflux = outfluxes (e.g. urinary 
output of Ca). These 8 pools included 3 pools of Ca 
in bone, extracellular space (serum), and intestine, 
4 pools of P in bone, serum, intracellular space, and 
kidney, and 1 pool of PTH in parathyroid grand. No 
independent state variables were considered for Ca 
in kidney or intracellular space, or for P in intestine 
(see details in 8 and Appendix).
Modeling five FGF23-linked pathways
In addition to dynamical alterations of  three molecular 
regulators  (PTH,  calcitriol,  and  1α-hydroxylase) 
in the previous model, the dynamical alteration of 
FGF23 was added in the current model as a mineral 
metabolism regulator (Fig. 1B). The total amount of 
FGF23 in serum, Q FGF23 (pg), was modeled:
  d(QFGF23)/dt = JFGF23 - δ . QFGF23  (2)
where JFGF23 = rate of  FGF23 secretion (pmole/hr), 
and δ = rate factor for FGF23 degradation (0.8 h-1). 
Since the secretion of  FGF23 is reported to be modulated 
by  the  serum  concentrations  of  P  and  calcitriol 
(pathways  I  and  II  in  Fig. 1B,  respectively), JFGF23 
was modeled:
JFGF23 (XP , Xcal) = {VP . XP/(XP + KP)}{Vcal . Xcal/(Xcal + Kcal)} 
(3)
in which XP, and Xcal were the serum concentrations 
of  P,  and  calcitriol.  The  parameters  (VP,  Vcal) 
and  (KP,  Kcal)  represented  the  maximum  rates  and 
Michaelis  constants  in  Michaelis-Menten  kinetics, 
respectively.
Three effects of FGF23 were considered in the 
extended  model:  inhibition  of  the  production  of 
calcitriol in the kidney tubule (pathway III), inhibition 
of the production of PTH by the parathyroid glands 
(pathway IV), and lowering of the renal threshold for 
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Figure 1. Schematic illustration of mineral metabolism in the described model with the action of FGF23. A) Five compartments in the model, where 
extracellular space contains plasma and extracellular fluid. Note that Ca = calcium, and P = phosphate. B) Modeling of FGF23 actions including 
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P (pathway V). In each pathway, the effect of FGF23 
was modeled in a form:
  Vmax . XFGF23/(XFGF23 + KM.M.),  
  or  
   Vmax . KM.M /(XFGF23 + KM.M.)  (4)
in which Vmax = maximum rate in Michaelis-Menten 
kinetics; KM.M. = affinity for the FGF23 receptor; and 
XFGF23 = serum concentration of FGF23. The former 
was used for stimulatory effects (pathway V) and the 
latter for inhibitory (pathways III and IV).
Dynamical simulation
Prior  to  numerical  simulations,  we  identified  the 
reference  states  (steady-states),  in  which  the  state 
variables  were  kept  constant.  Using  stepwise 
perturbations to the selected reference state variables, 
we evaluated the transient responses for 0–100 h, and 
a set of new steady states at 2000 h after an onset of 
perturbations. In order to avoid an impulsive jerk, 
stepwise perturbation was given using an exponential 
function in the initial perturbation phase with a time 
constant of 1 h. The key parameters employed in the 
study are listed (Table 1).
Analysis of FGF23 expression
Using  MLO-A5  osteocyte-like  cells,  we  conducted 
two experiments for investigation of FGF23 mRNA 
expression. In the first experiment, cells were grown 
either in the presence or absence of hydroxylapatite 
[Ca10(PO4)6(OH)2]  and  examined  the  effects  of 
hydroxylapatite in the culture medium on the FGF23 
mRNA  level.  In  the  second  experiment,  cells  were 
grown  with  and  without  a  pharmacological  agent 
(pertussis  toxin;  an  inhibitor  of  G-protein  linked 
receptors)13 and tested whether expression of FGF23 
would  be  affected  by  blocking  a  G-protein  linked 
receptor as a potential phosphate sensor in bone cells.
In  both  experiments,  approximately  1 × 106 
cells  were  seeded  on  the  3D  collagen  matrix 
(20 mm  ×  40 mm  ×  2 mm;  Zimmer  Dental)  and 
cultured in αMEM medium containing 5% fetal bovine 
serum, 5% bovine serum and antibiotics (50 units/ml 
penicillin  and  50  µg/ml  streptomycin;  Invitrogen) 
for  two  days.  Deposition  of  hypdroxylapatite  was 
conducted by immersion of the collagen matrix in 
500 mM  Na2HPO4  solution  for  5 min  followed  by 
rinsing  in  water  and  immersion  in  500 mM  CaCl2 
solution for 5 min.14 The matrix was thoroughly rinsed 
in water. Pertussis toxin (Calbiochem) was administered 
for 1 day at a concentration of 100 or 500 ng/ml.
Total RNA was harvested using RNeasy mini kits 
(Qiagen),  and  reverse  transcription  was  conducted 
with high capacity cDNA reverse transcription kits 
(Applied  Biosystems).15  Quantitative  real-time 
PCR  was  performed  using ABI  7500  with  Power 
SYBR  green  PCR  master  mix  kits  (Applied 
Biosystems).  The  PCR  primers  were  FGF23 
(5’-GACCAGCTATCACCTACAGATCCAT-3’; 
5’-TGTAATCATCAGGGCACTGTAGATG-5’), 
and GAPDH (5’-TGCACCACCAACTGCTTAG-3’; 
5’-GGATGCAGGGATGATGTTC-3’).
The mRNA level of GAPDH was used as an internal 
control. In evaluation of the effect of hydroxylapatite 
on  FGF23  expression,  the  GAPDH  mRNA  levels 
in  the  two  samples  were  compared  and  the  ratio 
(GAPDH level in hydroxylapatite/GAPDH level in 
control) was calculated. The level of FGF23 mRNA 
in hydroxylapatite was then divided by this ratio, and 
Table 1. FGF23-linked parameters employed in the study.
FGF23 pathways effect Remark Value
General Rate of FGF23 degradation 0.8 h-1
Reference FGF23 concentration 0.03 ng/ml
i (P to FGF23) stimulatory Michaelis constant 0.03 mg/ml
ii (calcitriol to FGF23) stimulatory Michaelis constant 0.038 ng/ml
iii (FGF23 to calcitriol) inhibitory Michaelis constant 0.03 ng/ml
iV (FGF23 to PTh) inhibitory Michaelis constant 0.03 ng/ml
V (FGF23 to P) stimulatory Michaelis constant 0.03 ng/mlFGF23 in mineral metabolism
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the mean value of the FGF23 mRNA level in control 
was set to 1. In evaluation of the effect of pertussis 
toxin on FGF23 expression, the same normalization 
procedure based on the GAPDH mRNA levels was 
taken in which the FGF23 mRNA level for the sample 
with 0 ng/ml pertussis toxin was set to 1. Experiments 
were conducted three times.
Results
Responses to a stepwise increase  
in FGF23 secretion
Based  on  the  above  mentioned  formulation  of  the 
expression and actions of FGF23, we first evaluated the 
effects of the stepwise increase in the secretion of  FGF23 
on the regulatory and homeostatic variables such as 
the  concentrations  of  PTH,  calcitriol,  Ca,  and  P  in 
serum as well as the absorption and excretion amounts 
of Ca and P. In the transient responses (0–100 h) to 
an increase in FGF23 from 30 to 260 pg/ml, those 
variables  were  decreased  with  varying  temporal 
behaviors  (Fig. 2).  The  concentration  of  PTH,  for 
instance, was swiftly reduced within a few h followed by 
a gradual recovery, while the concentration of calcitriol 
was monotonously lowered. The concentrations of Ca 
and P in serum were steeply dampened in the initial 
∼10 h and they stayed at the lower levels. Interestingly, 
the maximum reduction was observed in the excretion 
amount of Ca, which became nearly zero in 10 h.
In order to characterize the chronic effects of the 
increase in FGF23, we evaluated the pseudo steady-state 
values (2000 h) (Fig. 3). The variables as a function of 
the level of  FGF23 including the concentrations of  PTH, 
calcitriol, Ca, and P in serum, and the absorption and 
excretion levels of  Ca and P exhibited a monotonous 
decrease as the level of FGF23 increased.
Responses to a stepwise increase  
in the uptake of P
To evaluate the effects of FGF23 actions in mineral 
metabolism, we next evaluated the responses of the 
state variables in the presence and absence of FGF23 
actions after a stepwise increase in the phosphate intake. 
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Figure 2. Transient responses (0–100 h) to a stepwise increase in FGF23. The variables include the concentrations of FGF23, PTh, calcitriol, calcium, 
and phosphate in serum, and the excretion levels of calcium and phosphate in urine.Yokota et al
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As predicted in the responses to the stepwise FGF23 
increase in Figures 2 and 3, the transient responses 
revealed that the model with FGF23 always reduced 
the levels of 7 state variables within 20 h (Fig. 4). The 
concentrations of PTH, calcitriol, Ca, and P in serum, 
for instance, were lowered by 17%, 23%, 9%, and 
10% in 100 h, respectively.
Consistent  with  the  transient  responses,  those 
variables (the concentrations of PTH, calcitriol, Ca, P in 
serum, the absorption levels of calcium and phosphate 
in intestine, and the excretion levels of calcium and 
phosphate in urine) at 2000 h after the onset of the 
increased phosphate intake in diet from 2 to 20 mM/h 
were significantly lowered in the presence of FGF23 
(Fig. 5). The observed reductions were more evident 
in the responses to a higher intake level of P.
Responses to a stepwise increase  
in Ca uptake
The effects of FGF23 in response to the increased 
uptake of Ca were opposite to those in response to 
the elevated uptake of P, since the stepwise increase 
in Ca uptake lowered the concentration of FGF23 in 
serum (Fig. 6). Although the FGF23 model presented 
virtually no influence on the absorption or excretion 
of Ca, it elevated the intestinal uptake and the urinary 
output of P. Furthermore, in the presence of FGF23 
actions the concentrations of PTH, calcitriol, Ca, and 
P in serum were elevated.
Responses to a stepwise increase  
in calcitriol or PTh
Numerical simulations were also conducted in response 
to  a  stepwise  increase  in  two  regulatory  factors 
(calcitriol or PTH), and the pseudo steady-state values 
(2000 h) in the presence and absence of FGF23 were 
evaluated. Although the synthesis of FGF23 is affected 
by calcitriol and not by PTH in the current model, the 
stepwise perturbations in both calcitriol and PTH altered 
the  level  of  FGF23.  First,  the  increase  in  calcitriol 
upregulated  the  level  of FGF23 (Fig. 7), while that 
in PTH downregulated in (Fig. 8). Second, compared 
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to the model without the actions of  FGF23 the stepwise 
elevation of calcitriol in the FGF23 model reduced the 
level of PTH. On contrary, the stepwise increase of 
PTH in the current model significantly elevated the 
concentration of calcitriol in serum.
Neither perturbation did not show any clear effects 
on the absorption of Ca in intestine, but they changed 
the  absorption  and  excretion  of  P.  In  accordance 
with the predicted increase in FGF23, the stepwise 
input of calcitriol decreased the intestinal uptake and 
the urinary output of P. In concert to the simulated 
decrease in FGF23, on the other hand, the stepwise 
elevation of PTH increased the intestinal absorption 
and the urinary excretion of P.
expression of FGF23 in hydroxylapatite-
deposited collagen matrix
The FGF23 mRNA level was unregulated in the culture 
that was rich in Ca and phosphate (hydroxylapatite). 
Quantitative  real-time  PCR  showed  that  the 
mRNA level of FGF23 was elevated 8.7 fold in the 
matrix  deposited  with hydroxylapatite  (Fig. 9A). 
Furthermore,  the  elevated  FGF23  mRNA  level 
in hydroxylapatite  was  suppressed  by  the  inhibitor 
of G-protein linked receptors approximately by 10% 
and 85% at the concentrations of 100 and 500 ng/ml 
pertussis toxin, respectively (Fig. 9B).
Discussion
The current study presented mathematical formulation 
of the metabolism of Ca and P including the actions of 
FGF23. Prior to the discovery of FGF23, the calcium-
PTH-calcitriol  axis has  been  considered  a  primary 
regulatory pathway in mineral metabolism. The major 
function  of  this  axis  is  maintenance  of  the  serum 
calcium level, while its role in the serum phosphate 
level  is  treated  secondarily.16  Recent  advances  in 
our  understanding  of  disorders  involving  mineral 
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metabolism have led to the FGF23-bone-kidney axis 
being added to the calcium-PTH-calcitriol pathway.17 
In response to an increase in the phosphate level in 
serum (pathway I), it is proposed that the expression 
of FGF23 is elevated in osteocytes in bone. However, 
no  phosphate  sensor has  been  identified.  The 
present experimentation for the first time activated 
expression  of  FGF23  in  osteocyte  cells  in  vitro, 
although hydroxylapatite  is  a  compound  consisting 
of calcium and phosphate. Furthermore, similarly to a 
calcium sensor,18 the mRNA expression analysis using 
pertussis toxin indicates a possibility that a phosphate 
sensor is also a G-protein linked receptor.
The  described  model  allows  prediction  of  the 
concentrations of FGF23, calcitriol, PTH, Ca, and P in 
serum together with the intestinal absorption and the 
urinary excretion of Ca and P in response to varying 
perturbations.  The  FGF23  elevation  is  considered 
to reduce production of calcitriol in the kidney and 
decrease absorption of calcium and phosphate from the 
intestine.19 Although the exact molecular mechanism is 
yet to be determined, numerical simulations revealed 
that the presence of FGF23 altered the levels of both 
Ca and P in serum through a complex interplay with 
calcitriol  and  PTH  (pathways  II–IV).  Calcitriol  is 
modeled to be stimulatory to the circulatory level of 
FGF23 in serum (pathway II), while PTH is predicted 
to be inhibitory in an indirect fashion.
The  current  model  should  be  further  refined 
using experimental and clinical data regarding the 
upstream  and  downstream  events  for  expression 
of  FGF23.  Furthermore,  the  parameter  values  in 
Table 1 need validations. Nevertheless, the recent 
clinical  studies  support  that  FGF23  inhibits  renal 
production of calcitriol (pathway III), downregulates 
PTH  release  (pathway  IV),  and  induces  renal 
phosphaturia  (pathway  V).20  Furthermore,  FGF23 
and PTH in serum are shown to be associated in vivo, 
supporting the assumption of the model that FGF23 
directly regulates PTH expression.21 Using both rats 
and ex vivo rat parathyroid cultures, it is reported 
that  FGF23  suppresses  expression  and  secretion 
of PTH.22
Physiological data from FGF23 mutations can be 
also used for validation of the role of FGF23. The 
FGF23 gene was identified by its mutations associated 
with autosomal dominant hypophosphatemic 
rickets,  which  is  an  inherited  phosphate  wasting 
disorder.17 Thereafter, a variety of disorders resulting 
from  FGF23  malfunctioning have  been  reported. 
These  disorders,  which  are  caused  by  mutations  in 
the  genes  that  directly  or  indirectly  interact  with 
FGF23,  include hyperphosphatemic  familial  tumoral 
calcinosis, hereditary hypophosphatemic  rickets  with 
hypercalciuria, autosomal recessive hypophosphatemic 
rickets,  and  X-linked  dominant hypophosphatemic 
rickets. Furthermore, clinical data from patients with 
chronic kidney diseases should be useful in evaluating 
the interactions among calcitriol, PTH, and FGF23.
In  summary,  the  described  mathematical  model 
allows  us  evaluation  of  the  dynamical  metabolic 
processes in Ca and P by considering the regulatory 
actions  of  calcitriol,  PTH,  and  FGF23.  Biological 
experimentation indicated a potential role of G-linked 
protein receptors in regulating expression of  FGF23 in FGF23 in mineral metabolism
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bone cells. Further evaluations are necessary to refine 
the model. The results herein support that the described 
model-based  approach  together  with  biological 
verification  is  useful  for  characterization  of  the 
dynamical metabolic responses, which is indispensable 
for development of quantitative treatment strategies 
for patients with metabolic disorders.
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Appendix
According to our previous model without considering 
the effects of FGF23,8 the rate of changes of the calcium 
pools in bone (Ċb) and plasma including extracellular 
fluid  (Ċp)  as  well  as  the  transportable  fraction  in 
intestine (Ċ  f
i) are expressed:
   C t Q Q b pb
c
bp
c ( ) = -   (A1)
   C t Q Q Q Q p bp
c
ip
c
pb
c
pu
c ( ) ( ) ( ) = + - +   (A2)
   C t K C K C i
f
i
f f ( ) ( ) = - - 1 2 1   (A3)
where Qxy
c
 = rate of a calcium transfer from tissue “x” 
to tissue “y”. The dynamical changes of the phosphorus 
pools in bone (  P b), intracellular fluid (  P c), and plasma 
(  Pp) together with the transportable fraction in the 
kidney (  P
f
k) are expressed:
 P t Q pb Q bp b
P P ( ) = -   (A4)
 P t Q Q c pc
p
cp
p ( ) = -   (A5)
 P t G K P K P
f
k k
f
k
f ( ) { ( ) } = - - 5 6 1   (A6)
 P t Q Q Q Q Q Q p bp
p
cp
p
ip
p
pb
p
pc
p
pu
p ( ) ( ) ( ) = + + - + +  
 
(A7)
in  whichQxy
p  = rate  of  a  phosphorus  transfer  from 
tissue  “x”  to  tissue  “y”.  Lastly,  the  changes  of 
1α-hydroxylase ( hk), calcitriol ( vp), and PTH together 
with a dynamic alteration of secretory mass of the 
parathyroid gland ( πp and   π
f) are modeled:
 
 h t s h k h h k ( ) = -δ   (A8)
 
 v t s h v p v k v p ( ) = -δ   (A9)
 
 π δ π π π p p t s ( ) = -   (A10)
 
 Π Π Π
f f t t K K ( ) ( ) = - - 3 4 1   (A11)
The reference values in the above formulation are listed 
below assuming that the volume of plasma and extracellular 
fluid is 14 L.
Cb exchangeable pool amount of 
calcium in “bone (b)”
4.00 g
Cp Pool amount of calcium in 
“plasma and extracellular fluid (p)”
1.34 g
Ci
f transportable calcium fraction in 
“intestine (i)”
0.500
Pb exchangeable pool amount of 
phosphorus in “bone (b)”
1.86 g
Pc Pool amount of phosphorus in 
“cells (c)”
104 g
Pp Pool amount of phosphorus in 
“plasma and extracellular fluid (p)”
0.518 g
Pk
f Transportable phosphorus 
fraction in “kidney (k)”
0.500
vp Concentration of calcitriol 
[1,25(Oh)2vitamin D] in “plasma 
and extracellular fluid (p)”
37.5 pg/ml
πp concentration of pth in “plasma 
and extracellular fluid (p)”
36.4 pg/ml